Results 21 to 30 of about 12,105,273 (242)

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study

Swiss Medical Weekly, 2021
BACKGROUND International guidelines state that bone-targeted agents such as denosumab or zoledronic acid at doses used for bone metastasis are not indicated for patients with metastatic castration-sensitive prostate cancer (mCSPC) with bone ...
Sandro T. Stoffel, Roger von Moos, Beat Thürlimann, Richard Cathomas, Silke Gillessen, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Anita Feller, Corinne Schär, Daniel Dietrich, Matthias Schwenkglenks, Judith E. Lupatsch, Michael Mark   +13 more
doaj   +1 more source

Skeletal-Related Events (SRE) in Prostate Cancer: A Report of Two Cases

Folia Medica Indonesiana, 2021
A skeletal-related event (SRE) is an event occurring due to bone metastasis in prostate cancer. SREs are usually marked by pain, pathological fractures, spinal cord compression, hypercalcemia, or bone metastasis requiring radiotherapy or operation.
Anak Agung Ngurah Oka Diatmika, Sunaryo Hardjowijoto   +1 more
doaj   +1 more source

Bone health and therapeutic agents in advanced prostate cancer

Frontiers in Bioscience-Landmark, 2022
Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of ...
Maria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, David Buchser, Jorge Pastor, Xavier Maldonado, Juan Zafra, Alison C. Tree, Renée Bultijnck, Paul Sargos, Piet Ost, Felipe Couñago   +11 more
doaj   +1 more source

Supplemental Tables: Factors Associated with Skeletal-Related Events in Patients with Bone Metastatic Melanoma: A Retrospective Study of 481 Patients

, 2022
The following supplemental tables are for the benefit of the reviewers only.Supplemental Table 1. Patient baseline characteristics comparing patients with and without the occurrence of skeletal-related events throughout the study period.
Shimizu, M (via Mendeley Data), Shimizu, Michelle   +1 more
core   +1 more source

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis

Cancer Medicine, 2016
The purpose of this study was to estimate the risk of developing skeletal‐related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients.
Arif Hussain, Abdalla Aly, C. Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha   +5 more
doaj   +1 more source

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Bone Reports
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or ...
Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos   +9 more
doaj   +1 more source

Regulation of skeletal muscle plasticity by the transcriptional coregulators PGC-1α and NCoR1 [PDF]

, 2013
Skeletal muscle plasticity is regulated by a wide range of factors, among which environmental stimuli such as exercise play a central role. Importantly, changes in skeletal muscle phenotype exert a direct impact on health and risk to premature death.
Pérez-Schindler, Joaquín
core   +1 more source

Percentage of skeletal-related events (SREs) occurring in patients with bone metastases from gastric cancer.

, 2013
Percentage of skeletal-related events (SREs) occurring in patients with bone metastases from gastric cancer.
Saverio Cinieri (477380), Vincenzo Catalano (477369), Ferdinando Riccardi (477373), Nicola Silvestris (477360), Elisa Giommoni (477370), Alessandro Bertolini (477378), Antonio Bernardo (477366), Sandro Barni (477365), Alessandro Comandone (477371), Raimondo Ferrara (477374), Rossana Berardi (477376), Amalia Azzariti (477383), Antonio Febbraro (14646), Antonio Trogu (477375), Paolo Pedrazzoli (133344), Anna Elisabetta Brunetti (477382), Teresa Gamucci (477362), Maria Antonietta Satolli (477367), Evaristo Maiello (477372), Daniele Santini (222870), Francesco Pantano (222879), Silvana Leo (477377), Teresa Di Palma (477364), Toni Ibrahim (477361), Fernando De Vita (477363), Paola Bertocchi (477368), Salvatore Pisconti (477381), Francesco Angelini (477379), Antonio Russo (168018)   +28 more
core   +1 more source

Regulation of skeletal muscle mass through stretch-induced signaling events.

, 2004
Regulation of skeletal muscle mass through stretch-induced signaling ...
Troy A. Hornberger (7980944)
core   +4 more sources

The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study

BMC Cancer
Background Daratumumab (Dara), a humanized IgGκ monoclonal antibody targeting CD38, has shown significant efficacy in the treatment of multiple myeloma (MM).
Xinrong Li, Hua Wang, Yizhen Li, Jing Zhou, Nianhui Yang, Xiaolei Wei, Xiangran Cai, Zeyu Xiao, Juan Du, Hui Zeng   +9 more
doaj   +1 more source